# A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer

> **NCT02716792** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 334 (actual)

## Conditions studied

- Pain; Bone Neoplasms; Neoplasm Metastasis

## Interventions

- **DRUG:** Ibandronate

## Key facts

- **NCT ID:** NCT02716792
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-06
- **Final completion:** 2008-08
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2016-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716792, "A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02716792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*